Skip to content
Drug and Device World
Home
News
Pharma News
Medical Device News
Obesity News
Sustainability
Latest in Sustainability
Sustainability News
Company Progress Report and Analysis
Expert Interviews
AI & Tech
Latest in AI and Technology
AI and Technology News
Expert Interviews
Features
Latest Features
In Conversation With
Exclusive Analysis
Wellness & Lifestyle
Members Only
Become A Member
Login
Manage Membership
FAQs
Contact Us
About the Author
Contact Us
Advertise
Search
Obesity
From gut resets to microbiome rejuvenation: DDW 2026 highlights transformative approaches to digestive health
May 5, 2026
2025 in Review: Global biotech and funding trends
February 13, 2026
Amgen’s new data reinforce weight regain after GLP-1 discontinuation
November 18, 2025
Phenomix expands evidence for GLP-1 response predicting MyPhenome test
November 4, 2025
Aphaia’s coated-glucose platform: A new approach to obesity treatment
October 24, 2025
FDA expands Novo Nordisk’s Rybelsus label to include cardiovascular risk reduction
October 22, 2025
Aphaia Pharma publishes Phase I and II data for obesity therapy
September 24, 2025
EASD 2025: Amgen highlights real-world challenges in obesity management
September 22, 2025
EASD 2025: MitoRx reports preclinical data on muscle preservation in obesity
September 18, 2025
Precision, not hype: Phenomix CEO on the future of obesity treatment
July 30, 2025
Currax targets affordability with new Contrave cash-pay program
July 22, 2025
Pila Pharma secures funding to advance obesity drug development
July 10, 2025
Next Page
»
Home
Membership
Loading Comments...
Write a Comment...
Email
Name
Website
